Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, Noriko Tanaka, Hanna Bandos, Patrick G Gavin, Debora Fumagalli, Lynn C Goldstein, Nour Sneige, Eike Burandt, Yusuke Taniyama, Olga L Bohn, Ahwon Lee, Seung-Il Kim, Megan L Reilly, Matthew Y Remillard, Nicole L Blackmon, Seong-Rim Kim, Zachary D Horne, Priya Rastogi, Louis Fehrenbacher, Edward H Romond, Sandra M Swain, Eleftherios P Mamounas, D Lawrence Wickerham, Charles E Geyer, Joseph P Costantino, Norman Wolmark, Soonmyung Paik
BACKGROUND: National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31 suggested the efficacy of adjuvant trastuzumab, even in HER2-negative breast cancer. This finding prompted us to develop a predictive model for degree of benefit from trastuzumab using archived tumor blocks from B-31. METHODS: Case subjects with tumor blocks were randomly divided into discovery (n = 588) and confirmation cohorts (n = 991). A predictive model was built from the discovery cohort through gene expression profiling of 462 genes with nCounter assay...
December 4, 2013: Journal of the National Cancer Institute